<DOC>
	<DOCNO>NCT00463541</DOCNO>
	<brief_summary>To evaluate safety efficacy solifenacin succinate subject overactive bladder symptom ( urgency , without urge incontinence , usually frequency nocturia ) .</brief_summary>
	<brief_title>Open-label Study Efficacy Safety VESIcare® Patients With Overactive Bladder Symptoms</brief_title>
	<detailed_description>Study include 24 week extension occur due FDA approval product .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Symptoms OAB ( urgency , without urge incontinence , usually frequency nocturia ) ≥3 month . Patients may include another OAB medication ; however , patient must washout OAB medication least 7 day prior receive solifenacin succinate . Previous nondrug treatment OAB allow establish least 4 week prior study entry continue throughout study . Significant stress incontinence mixed stress/urge incontinence stress predominant factor Evidence urinary tract infection ; chronic inflammation interstitial cystitis bladder stone Clinically significant outflow obstruction ( benign prostatic hyperplasia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Urinary Bladder , Overactive</keyword>
	<keyword>Urgency</keyword>
	<keyword>VESIcare®</keyword>
	<keyword>Solifenacin succinate</keyword>
</DOC>